Substituted naphthyridinone compounds useful as T cell activators

US10954238B1 · kind B1 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Upender Velaparthi · Princeton Junction, US
• Louis S. Chupak · Old Saybrook, US
• Chetan Padmakar Darne · Orange, US
• Min Ding · Dobbs Ferry, US
• Robert G. Gentles · Killingworth, US
• Yazhong Huang · Wallingford, US
• Manjunatha Narayana Rao Kamble · Bengaluru, IN
• Scott W. Martin · Middletown, US
• Raju Mannoori · Bengaluru, IN
• Ivar M. McDonald · East Haddam, US
• Richard E. Olson · Wilmington, US
• Hasibur Rahaman · Bengaluru, IN
• Prasada Rao Jalagam · Bengaluru, IN
• Saumya Roy · Bengaluru, IN
• Gopikishan Tonukunuru · Kanchinakote, IN
• Sivasudar Velaiah · Hosur, IN
• Jayakumar Sankara Warrier · Bengaluru, IN
• Xiaofan Zheng · Cheshire, US
• John S. Tokarski · Princeton, US
• Bireshwar Dasgupta · Middletown, US
• Kotha Rathnakar Reddy · Warangal, IN
• Thiruvenkadam Raja · Hosur, IN

Key dates

• Filing date: Apr 8, 2020
• Grant date: Mar 23, 2021
• Expiry date: Apr 8, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.